This website is using cookies to provide a good browsing experience. These include essential cookies that are necessary for the operation of the site, as well as others that are used for anonymous statistical purposes.

This website is using cookies to provide a good browsing experience. These include essential cookies that are necessary for the operation of the site, as well as others that are used for anonymous statistical purposes.

Your cookie preferences have been saved.
Press Release - March 28, 2023

Backed by cutting edge research, our flexible centralized lab services allow biotech and pharma customers developing IgE-mediated immune and allergy therapies to generate high quality efficacy and safety assessment data quickly and reliably, throughout the product development lifecycle.

Please get in touch with us, and we will be happy to discuss your specific requests.

Lead Compound Identification

ATANIS enables development-stage customers to screen compounds for effectiveness.

Whether you are looking to assess a given compound or drug against a defined allergen (peanuts, shrimp, pollen, etc.), or screen a wide range of compounds for efficacy against a given target, for example IgE, we can support you through our fee-for-service approach, which delivers standardized results quickly.


  • Stable cell line: Our lab-grown mast cell line performs the same way every day to remove the variability inherent in animal testing and other activation tests.

  • High performance: The high sensitivity of our mast cells results in unprecedented activation potential, while keeping baseline background extremely low.

  • Accelerated development: Our assays are standardized, and work with any donor, not just those which are highly reactive.

  • Unlimited supply of cells, available on demand: Our cells are always ready to work, which translates into simplified workflows and quicker results.

Efficacy Testing during Clinical Trials

Using our functional allergy screening test, customers can easily understand and quantify efficacy of their drug on the decrease in a patient’s allergic reactivity over time.

Customers trust us to process patient samples in our centralized lab to generate objective, quantitative, standardized data about treatment efficacy throughout the duration of a study.

Working with a standardized functional assay enables us to be flexible and as fast as customers need up to be.


  • High quality data: All patient samples are analyzed in a single centralized laboratory, which minimizes the variance inherent in data generated in multi-center studies.

  • Flexibility: Working with patient serum or plasma removes limitations associated with working with whole blood and fragile basophils and allows both retro- and prospective studies.

  • Comparability over time: Working with the same cell line throughout the duration of the clinical trial improves the quality of the longitudinal analysis of patient sera.

Drug Safety Assessment

All drugs have the potential to cause allergic reactions in some patients, and our screening platform helps you understand the reasons. Whether it is the adjuvants, or the biologic material, we can identify the source of allergic hypersensitivity reactions because we can test compounds or additives directly on mast cells, or mast cells sensitized with patient sera or model immunoglobulins.

Using our unique technology, ATANIS Biotech can assess the potential of a drug to induce cell activation, as well as spontaneous activation.


  • High reproducibility: Working with our standardized assay yields results which are reproducible and comparable throughout the duration of a study.

  • Highly customizable: If your company has specific needs, we can work together to develop an assay which is tailored to your needs and generates the results you need.

  • Stability: Allows quality control of batch preparations and batch-to-batch comparisons to ensure maximum patient safety.

Hypersensitivity Detection in Plasma-extracted Products

We help customers assess the risk of anaphylactogenic potential of purified donor plasma products such as intravenous immunoglobulins.

This enables them to identify individuals within their donor pool, whose plasma triggers hypersensitivity reactions in recipients, and take appropriate action to ensure the integrity of the batches they place on the market.

Inversely, we are also able to test individual donors, or pools thereof, for the potential of their plasma to trigger hypersensitivity reactions in recipients using our customizable mast cell assay, thereby ensuring that reactive donor plasma are excluded from future products.


  • Promote recipient safety: Ensure that batches are not contaminated before distribution

  • Early detection: Identify problematic donors before their plasma enters the product pool and reduce the risk of product recalls.

We are actively developing a new diagnostic test for primary allergy screening and treatment follow up. The test will become available to primary physicians and specialists soon.